Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Human Genome Sciences has completed enrollment and initial dosing of patients in a randomized Phase II trial of HGS-ETR1 in combination with the chemotherapy agents paclitaxel and carboplatin as first-line therapy in advanced non-small cell lung cancer.
Subscribe to our email newsletter
The non-small cell lung cancer (NSCLC) trial is a randomized, multi-center, open-label Phase II study to evaluate the efficacy and safety of HGS-ETR1 in combination with carboplatin and paclitaxel as first-line therapy in the treatment of advanced non-small cell lung cancer (Stage IIIB or IV).
Approximately 111 patients have been randomly assigned to one of three treatment groups and treated with either the two-agent combination of carboplatin and paclitaxel or the three-agent combination of carboplatin, paclitaxel, and HGS-ETR1 at either 10mg/kg or 30mg/kg.
Gilles Gallant, vice president of clinical research – oncology at Human Genome Sciences, said: “HGS-ETR1 is the most advanced of any product in development that targets the Trail apoptotic pathway. The NSCLC study is one of three ongoing Human Genome Sciences (HGS) trials designed to evaluate combinations of HGS-ETR1 with chemotherapeutic agents for the treatment of specific cancers.”